FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3075864477> ?p ?o ?g. }

• W3075864477 endingPage "197.e23" @default.
• W3075864477 startingPage "197.e1" @default.
• W3075864477 abstract "Background Uterine leiomyosarcoma is a rare and aggressive gynecologic malignancy originating in the myometrium of the uterine corpus that tends to recur even after complete surgical excision. Current therapeutic agents have only modest effects on uterine leiomyosarcoma. Although antibodies and antibody-drug conjugates have been recognized as useful targeted therapies for other cancers, no study has yet evaluated the effects of this approach on uterine leiomyosarcoma. Objective This study aimed to examine the activity of tumoral CD70 in uterine leiomyosarcoma and assess the antitumor activity of CD70–antibody-drug conjugate treatment in uterine leiomyosarcoma. Study Design Target membrane proteins were screened by profiling and comparing membrane protein expression in 3 uterine leiomyosarcoma cell lines (SK-UT-1, SK-LMS-1, and SKN) and normal uterine myometrium cells using the isobaric tags for relative and absolute quantitation labeling method. Western blotting, fluorescence-activated cell sorting analyses, and immunohistochemistry were used to examine CD70 expression in the membrane proteins in uterine leiomyosarcoma cell lines and clinical samples. We developed an antibody-drug conjugate with a monoclonal antibody of the target membrane protein linked to monomethyl auristatin F and investigated its antitumor effects against uterine leiomyosarcoma (in vitro, in vivo, and in patient-derived xenograft models). Results CD70 was identified as a specific antigen highly expressed in uterine leiomyosarcoma cell lines. Of the 3 uterine leiomyosarcoma cell lines, CD70 expression was confirmed in SK-LMS-1 cells by western blotting and fluorescence-activated cell sorting analysis. CD70 overexpression was observed in 19 of 21 (90.5%) tumor specimens from women with uterine leiomyosarcoma. To generate CD70–antibody-drug conjugate, anti-CD70 monoclonal antibody was conjugated with a novel derivative of monomethyl auristatin F. CD70–antibody-drug conjugate showed significant antitumor effects on SK-LMS-1 cells (half maximal inhibitory concentration, 0.120 nM) and no antitumor effects on CD70-negative uterine leiomyosarcoma cells. CD70–antibody-drug conjugate significantly inhibited tumor growth in the SK-LMS-1 xenograft mouse model (tumor volume, 129.8 vs 285.5 mm3; relative reduction, 54.5%; P<.001) and patient-derived xenograft mouse model (tumor volume, 128.1 vs 837.7 mm3; relative reduction, 84.7%; P<.001). Conclusion Uterine leiomyosarcoma tumors highly express CD70 and targeted therapy with CD70–antibody-drug conjugate may have a potential therapeutic implication in the treatment of uterine leiomyosarcoma. Uterine leiomyosarcoma is a rare and aggressive gynecologic malignancy originating in the myometrium of the uterine corpus that tends to recur even after complete surgical excision. Current therapeutic agents have only modest effects on uterine leiomyosarcoma. Although antibodies and antibody-drug conjugates have been recognized as useful targeted therapies for other cancers, no study has yet evaluated the effects of this approach on uterine leiomyosarcoma. This study aimed to examine the activity of tumoral CD70 in uterine leiomyosarcoma and assess the antitumor activity of CD70–antibody-drug conjugate treatment in uterine leiomyosarcoma. Target membrane proteins were screened by profiling and comparing membrane protein expression in 3 uterine leiomyosarcoma cell lines (SK-UT-1, SK-LMS-1, and SKN) and normal uterine myometrium cells using the isobaric tags for relative and absolute quantitation labeling method. Western blotting, fluorescence-activated cell sorting analyses, and immunohistochemistry were used to examine CD70 expression in the membrane proteins in uterine leiomyosarcoma cell lines and clinical samples. We developed an antibody-drug conjugate with a monoclonal antibody of the target membrane protein linked to monomethyl auristatin F and investigated its antitumor effects against uterine leiomyosarcoma (in vitro, in vivo, and in patient-derived xenograft models). CD70 was identified as a specific antigen highly expressed in uterine leiomyosarcoma cell lines. Of the 3 uterine leiomyosarcoma cell lines, CD70 expression was confirmed in SK-LMS-1 cells by western blotting and fluorescence-activated cell sorting analysis. CD70 overexpression was observed in 19 of 21 (90.5%) tumor specimens from women with uterine leiomyosarcoma. To generate CD70–antibody-drug conjugate, anti-CD70 monoclonal antibody was conjugated with a novel derivative of monomethyl auristatin F. CD70–antibody-drug conjugate showed significant antitumor effects on SK-LMS-1 cells (half maximal inhibitory concentration, 0.120 nM) and no antitumor effects on CD70-negative uterine leiomyosarcoma cells. CD70–antibody-drug conjugate significantly inhibited tumor growth in the SK-LMS-1 xenograft mouse model (tumor volume, 129.8 vs 285.5 mm3; relative reduction, 54.5%; P<.001) and patient-derived xenograft mouse model (tumor volume, 128.1 vs 837.7 mm3; relative reduction, 84.7%; P<.001). Uterine leiomyosarcoma tumors highly express CD70 and targeted therapy with CD70–antibody-drug conjugate may have a potential therapeutic implication in the treatment of uterine leiomyosarcoma." @default.
• W3075864477 created "2020-08-24" @default.
• W3075864477 creator A5000713007 @default.
• W3075864477 creator A5002638004 @default.
• W3075864477 creator A5002700571 @default.
• W3075864477 creator A5002981802 @default.
• W3075864477 creator A5004882510 @default.
• W3075864477 creator A5009314886 @default.
• W3075864477 creator A5016144414 @default.
• W3075864477 creator A5018600874 @default.
• W3075864477 creator A5020771892 @default.
• W3075864477 creator A5030259502 @default.
• W3075864477 creator A5032604446 @default.
• W3075864477 creator A5050474676 @default.
• W3075864477 creator A5055405608 @default.
• W3075864477 creator A5058902589 @default.
• W3075864477 creator A5071731375 @default.
• W3075864477 creator A5086167183 @default.
• W3075864477 creator A5091476969 @default.
• W3075864477 date "2021-02-01" @default.
• W3075864477 modified "2023-10-16" @default.
• W3075864477 title "CD70 antibody-drug conjugate as a potential therapeutic agent for uterine leiomyosarcoma" @default.
• W3075864477 cites W1499206957 @default.
• W3075864477 cites W1551534581 @default.
• W3075864477 cites W1557340160 @default.
• W3075864477 cites W1968211025 @default.
• W3075864477 cites W1968438607 @default.
• W3075864477 cites W1969179435 @default.
• W3075864477 cites W1969851330 @default.
• W3075864477 cites W1976549140 @default.
• W3075864477 cites W2006899747 @default.
• W3075864477 cites W2013547232 @default.
• W3075864477 cites W2018204959 @default.
• W3075864477 cites W2024265215 @default.
• W3075864477 cites W2027616763 @default.
• W3075864477 cites W2030341765 @default.
• W3075864477 cites W2043958889 @default.
• W3075864477 cites W2059265067 @default.
• W3075864477 cites W2078843849 @default.
• W3075864477 cites W2079653398 @default.
• W3075864477 cites W2089887319 @default.
• W3075864477 cites W2098193186 @default.
• W3075864477 cites W2101776780 @default.
• W3075864477 cites W2119094378 @default.
• W3075864477 cites W2124514746 @default.
• W3075864477 cites W2128140185 @default.
• W3075864477 cites W2140292293 @default.
• W3075864477 cites W2147360261 @default.
• W3075864477 cites W2158285723 @default.
• W3075864477 cites W2159744123 @default.
• W3075864477 cites W2162148525 @default.
• W3075864477 cites W2166023644 @default.
• W3075864477 cites W2172342370 @default.
• W3075864477 cites W2179836657 @default.
• W3075864477 cites W2203423087 @default.
• W3075864477 cites W2295168822 @default.
• W3075864477 cites W2315322079 @default.
• W3075864477 cites W2341089209 @default.
• W3075864477 cites W2610035536 @default.
• W3075864477 cites W2698787169 @default.
• W3075864477 cites W2762797139 @default.
• W3075864477 cites W2766493195 @default.
• W3075864477 cites W2766710074 @default.
• W3075864477 cites W2767025650 @default.
• W3075864477 cites W2768729693 @default.
• W3075864477 cites W2775816941 @default.
• W3075864477 cites W2801640510 @default.
• W3075864477 cites W2909655571 @default.
• W3075864477 cites W2912054299 @default.
• W3075864477 cites W2921589168 @default.
• W3075864477 cites W3004433533 @default.
• W3075864477 cites W3008694552 @default.
• W3075864477 cites W3009291261 @default.
• W3075864477 cites W4229526665 @default.
• W3075864477 cites W4674812 @default.
• W3075864477 cites W2963616753 @default.
• W3075864477 doi "https://doi.org/10.1016/j.ajog.2020.08.028" @default.
• W3075864477 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32822640" @default.
• W3075864477 hasPublicationYear "2021" @default.
• W3075864477 type Work @default.
• W3075864477 sameAs 3075864477 @default.
• W3075864477 citedByCount "7" @default.
• W3075864477 countsByYear W30758644772021 @default.
• W3075864477 countsByYear W30758644772023 @default.
• W3075864477 crossrefType "journal-article" @default.
• W3075864477 hasAuthorship W3075864477A5000713007 @default.
• W3075864477 hasAuthorship W3075864477A5002638004 @default.
• W3075864477 hasAuthorship W3075864477A5002700571 @default.
• W3075864477 hasAuthorship W3075864477A5002981802 @default.
• W3075864477 hasAuthorship W3075864477A5004882510 @default.
• W3075864477 hasAuthorship W3075864477A5009314886 @default.
• W3075864477 hasAuthorship W3075864477A5016144414 @default.
• W3075864477 hasAuthorship W3075864477A5018600874 @default.
• W3075864477 hasAuthorship W3075864477A5020771892 @default.
• W3075864477 hasAuthorship W3075864477A5030259502 @default.
• W3075864477 hasAuthorship W3075864477A5032604446 @default.
• W3075864477 hasAuthorship W3075864477A5050474676 @default.
• W3075864477 hasAuthorship W3075864477A5055405608 @default.

• next